Literature DB >> 11294957

Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice.

J Edmeads1, J M Láinez, J L Brandes, J Schoenen, F Freitag.   

Abstract

Migraine is not always well managed in clinical practice, often being under-diagnosed and under-treated. As a result, many sufferers never consult a physician or lapse from care after physician contact. Although most migraine care is provided by general practitioners, others, including specialists, emergency room physicians, pharmacists, and alternative practitioners, may also be involved. A method of standardizing clinical information about migraine is essential for coordinated, logical, and systematic care. The impact of migraine on the patient is an important clinical parameter but one that is seldom inquired about, perhaps because it exhibits such marked variability among and within individuals. Headache-related disability can be an objective and measurable index of this impact. The Migraine Disability Assessment (MIDAS) Questionnaire is a simple and validated instrument with potential for use in clinical practice, research, and public health. It can improve communication between patients and health-care professionals regarding the impact of migraine which, in turn, allows tailoring of the intensity of treatment to the severity of the illness. Changes in the MIDAS score may serve as an end point in assessing treatment efficacy. In populations, MIDAS scores may indicate the burden of migraine in the community and spark public health initiatives to improve management.

Entities:  

Mesh:

Year:  2001        PMID: 11294957     DOI: 10.1212/wnl.56.suppl_1.s29

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Migraine treatment in developmental age: guidelines update.

Authors:  Laura Papetti; Alberto Spalice; Francesco Nicita; Maria Chiara Paolino; Rosa Castaldo; Paola Iannetti; Maria Pia Villa; Pasquale Parisi
Journal:  J Headache Pain       Date:  2010-03-27       Impact factor: 7.277

2.  Migraine care among different ethnicities: do disparities exist?

Authors:  Robert A Nicholson; Megan Rooney; Kelly Vo; Erinn O'Laughlin; Melanie Gordon
Journal:  Headache       Date:  2006-05       Impact factor: 5.887

Review 3.  Acute treatment of migraines.

Authors:  Arnaldo N Da Silva; Stewart J Tepper
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

4.  Acute Treatment of Migraine Headache.

Authors:  Marcelo E. Bigal; Richard B. Lipton
Journal:  Curr Treat Options Neurol       Date:  2003-11       Impact factor: 3.598

5.  A six-item short-form survey for measuring headache impact: the HIT-6.

Authors:  M Kosinski; M S Bayliss; J B Bjorner; J E Ware; W H Garber; A Batenhorst; R Cady; C G H Dahlöf; A Dowson; S Tepper
Journal:  Qual Life Res       Date:  2003-12       Impact factor: 4.147

6.  Improved migraine management in primary care: results of a patient treatment experience study using zolmitriptan orally disintegrating tablet.

Authors:  G Shapero; A Dowson; J-P Lacoste; P Almqvist
Journal:  Int J Clin Pract       Date:  2006-12       Impact factor: 2.503

7.  Comparison of validity and reliability of the Migraine disability assessment (MIDAS) versus headache impact test (HIT) in an Iranian population.

Authors:  Abbas Ghorbani; Ahmad Chitsaz
Journal:  Iran J Neurol       Date:  2011

8.  Supraorbital Rim Syndrome: Definition, Surgical Treatment, and Outcomes for Frontal Headache.

Authors:  Robert R Hagan; Michael A Fallucco; Jeffrey E Janis
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-07-12

9.  Validity and reliability of the Portuguese version of the modified Migraine Disability Assessment.

Authors:  Pedro L Ferreira; Isabel Luzeiro; Margarida Lopes; André Jorge; Bruno Silva; Lara Ferreira
Journal:  BMC Neurol       Date:  2021-02-06       Impact factor: 2.474

10.  What is the impact of physician communication and patient understanding in the management of headache?

Authors:  Meenal Patwardhan; Remy R Coeytaux; Rajeshwari Deshmukh; Gregory Samsa
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.